Skip to main content
SpringerLink
Log in

Hallucinogens: An update

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Research of hallucinogen abuse rarely extends beyond epidemiology and observed pathology. Even less research has been completed on the special circumstances surrounding the religious use of hallucinogens or on potential therapeutic applications. Rather than offer another basic review on the well-known hazards of illicit hallucinogen use, this paper provides an overview and practice recommendations on compounds the clinician may be less familiar with, such as the botanical plant Salvia divinorum, the drug 3,4-methylenedioxymethamphetamine (“ecstasy”) and synthetic hallucinogen analogs. The often-warned, but rarely occurring, hazard of hallucinogen persisting perception disorder (“flashbacks”) is also reviewed with treatment recommendations provided. The current status of clinical research with the hallucinogens is presented, with case vignettes suggesting hallucinogens may have anti-addictive applications. The special circumstances surrounding the religious, nondrug use of hallucinogens as sacred sacraments in the US and elsewhere are also presented. It is hoped that the reader will gain a more nuanced understanding of how these physiologically nonaddictive drugs may offer legitimate benefits in modern society. By appreciating that such benefits may one day be borne out by careful, methodologically sound research, clinicians should be better armed in raising the topic of hallucinogen use and abuse with their patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Strassman RJ: Adverse reactions to psychedelic drugs: a review of the literature. J Nerv Ment Dis 1984, 172:577–595. This paper is the “gold-standard” review of adverse reactions from hallucinogens and takes great care in discussing the extensive clinical research with hallucinogens that occurred primarily from the 1950s through early 1970s. Strassman went on to publish original research on the dose-response effects of the hallucinogen dimethyltryptamine (see Strassman RJ, Qualls C: Dose-response study of N,N-dimethyltryptamine in humans, I: neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 1994, 51:85–97.).

    Article  PubMed  CAS  Google Scholar 

  2. El-Mallakh RS, Halpern JH, Abraham HD: Substance abuse: hallucinogen and MDMA-related disorders. In Psychiatry. Edited by Tasman A, Lieberman J, Kay J. London: John Wiley & Sons, Ltd.; 2003:1046–1065. This is the most recent textbook review on hallucinogens and is the first to discuss how hallucinogens are drugs of abuse while remaining bona fide religious sacraments in traditional societies and some religions.

    Google Scholar 

  3. Siebert D: Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 1994, 43:53–56.

    Article  PubMed  CAS  Google Scholar 

  4. Valdes LJ: Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs 1994, 26:277–283.

    PubMed  Google Scholar 

  5. Roth BL, Baner K, Westkaemper R, et al.: Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. PNAS 2002, 99:11934–11939.

    Article  PubMed  CAS  Google Scholar 

  6. Halpern JH, Pope HG: Hallucinogens on the Internet: a vast new source of underground drug information. Am J Psychiatry 2001, 158:481–483. This paper provides an extensive review of the types of information available on hallucinogens via the Internet.

    Article  PubMed  CAS  Google Scholar 

  7. Cole JC, Sumnall HR: Altered states: the clinical effects of Ecstasy. Pharmacol Ther 2003, 98:35–58.

    Article  PubMed  CAS  Google Scholar 

  8. Office of Applied Studies: Results from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of national findings. (DHHS Publication No. SMA 02-3758, NHSDA Series H-17). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2002.

  9. Johnston LD, O’Malley PM, Bachman JG: Monitoring the future national results on adolescent drug use: overview of key findings (National Institutes of Health Publication No. 03-5374). Bethesda: National Institute on Drug Abuse; 2003.

    Google Scholar 

  10. Pope HG, Ionescu-Pioggia M, Pope KW: Drug use and lifestyle among college undergraduates: a 30-year longitudinal study. Am J Psychiatry 2001, 158:1519–1521.

    Article  PubMed  Google Scholar 

  11. Klitzman RL, Pope HG, Hudson JI: MDMA (“Ecstasy”) abuse and high-risk sexual behaviors among 169 gay and bisexual men. Am J Psychiatry 2000, 157:1162–1164.

    Article  PubMed  CAS  Google Scholar 

  12. Colfax GN, Mansergh G, Guzman R, et al.: Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr 2001, 28:373–379.

    PubMed  CAS  Google Scholar 

  13. Breslau K: The ‘sextasy’ craze. Clubland’s dangerous party mix: Viagra and ecstasy. Newsweek 2002, 139:30.

    PubMed  Google Scholar 

  14. Parrott AC: Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioral indices of change. Neuropsychobiology 2000, 42:17–24.

    Article  PubMed  CAS  Google Scholar 

  15. Thomasius R, Petersen K, Buchert R, et al.: Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 2003, 167:85–96. This recent study is one of the few to attempt careful control for most of the mentioned methodologic limitations. Findings did not corroborate earlier studies claiming residual functional deficits on verbal measures.

    CAS  Google Scholar 

  16. Kish SJ: How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 2002, 71:845–855.

    Article  PubMed  CAS  Google Scholar 

  17. Soar K, Turner JJ, Parrott AC: Psychiatric disorders in Ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum Psychopharmacol 2001, 16:641–645.

    Article  PubMed  Google Scholar 

  18. Versiani M: A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia). World J Biol Psychiatry 2000, 1:27–33.

    Article  PubMed  CAS  Google Scholar 

  19. Henry JA, Fallon JK, Kicman AT, et al.: Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet 1998, 351:1784.

    Article  PubMed  CAS  Google Scholar 

  20. Shulgin A, Shulgin A: Tihkal: The Continuation. Berkeley: Transform Press; 1997.

    Google Scholar 

  21. Shulgin A, Shulgin A: Pihkal: A Chemical Love Story. Berkeley: Transform Press; 1991.

    Google Scholar 

  22. 2-C-T-7: Intent to Schedule. Federal Register 2002, 67:47343–47345.

  23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Press, Inc; 1994.

    Google Scholar 

  24. Halpern JH, Pope HG: Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003, 69:109–119.

    Article  PubMed  Google Scholar 

  25. Abraham HD: Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 1983, 40:884–889.

    PubMed  CAS  Google Scholar 

  26. Abraham H: Hallucinogen persisting perception disorder. Pract Rev Psychiatry 1998, 22:1–2.

    Google Scholar 

  27. Lerner AG, Finkel B, Oyffe I, et al.: Clonidine treatment for hallucinogen persisting perception disorder. Am J Psychiatry 1998, 155:1460.

    PubMed  CAS  Google Scholar 

  28. Vastag B: Addiction treatment strives for legitimacy. JAMA 2002, 288:3096–3101.

    Article  PubMed  Google Scholar 

  29. Pope HG: Tabernanthe iboga: an African narcotic plant of social importance. Economic Botany 1969, 23:174–184.

    Google Scholar 

  30. Glick SD, Maisonneuve IM, Szumlinski KK: 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of anti-addictive efficacy, toxicity, and mechanisms of action. Ann N Y Acad Sci 2000, 914:369–386.

    Article  PubMed  CAS  Google Scholar 

  31. Cappendijk SLT, Dzoljic MR: Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 1993, 241:261–265.

    Article  PubMed  CAS  Google Scholar 

  32. Glick SD, Rossman KL, Rao NC, et al.: Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology 1992, 31:497–500.

    Article  PubMed  CAS  Google Scholar 

  33. Szumlinski KK, Haskew RE, Balogun MY, et al.: Iboga compounds reverse the behavioral disinhibiting and corticosterone effects of acute methamphetamine: implications for their anti-addictive properties. Pharmacol Biochem Behav 2001, 69:485–491.

    Article  PubMed  CAS  Google Scholar 

  34. Halpern JH: The use of hallucinogens in the treatment of addiction. Addict Res 1996, 4:177–189. This paper carefully reviews this topic and concludes that hallucinogens remain possible therapeutic agents for addiction. Research ended not because of negative findings but because investigators were no longer willing to continue working with compounds blamed for contributing to the social upheaval of the 1960s.

    Google Scholar 

  35. Greer G, Tolbert R: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986, 18:319–327.

    PubMed  CAS  Google Scholar 

  36. Kurland AA: LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs 1985, 17:279–290.

    PubMed  CAS  Google Scholar 

  37. Grof S, Goodman LE, Richards WA, Kurland AA: LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 1973, 8:129–144.

    PubMed  CAS  Google Scholar 

  38. Pahnke WN, Kurland AA, Goodman LE, Richards WA: LSDassisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther 1969, 9:144–152.

    PubMed  CAS  Google Scholar 

  39. Kast E: Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatr Q 1967, 41:646–657.

    Article  PubMed  CAS  Google Scholar 

  40. Krupitsky EM, Grinenko AY: Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997, 29:165–183.

    PubMed  CAS  Google Scholar 

  41. Krupitsky E, Burakov A, Romanova T, et al.: Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 2002, 23:273–283.

    Article  PubMed  Google Scholar 

  42. Moreno FA, Delgado PL: Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry 1997, 154:1037–1038.

    PubMed  CAS  Google Scholar 

  43. Doblin R: A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoactive Drugs 2002, 34:185–194.

    PubMed  Google Scholar 

  44. Heffter Research Institute progress report: Available at http:// www.heffter.org/pages/activities/prog2002.html. Accessed July 10, 2003.

  45. Albaugh BJ, Anderson PO: Peyote in the treatment of alcoholism among Native Americans. Am J Psychiatry 1974, 131:1247–1250.

    PubMed  CAS  Google Scholar 

  46. Bergman RL: Navajo peyote use: its apparent safety. Am J Psychiatry 1971, 128:695–699.

    PubMed  CAS  Google Scholar 

  47. Halpern JH, Pope HG, Sherwood A, et al.: Neuropsychological effects of long-term hallucinogen use vs alcoholism in Native Americans: cultural limitations of tests. Drug Alcohol Depend 2002, 66:S73-S74.

    Google Scholar 

  48. Halpern JH, Pope HG, Sherwood A, et al.: Neuropsychological effects of long-term hallucinogen use in Native Americans. Drug Alcohol Depend 2001, 63:S62.

    Google Scholar 

  49. Dorrance DL, Janiger O, Teplitz RL: Effect of peyote on human chromosomes: cytogenic study of the Huichol Indians of northern Mexico. JAMA 1975, 234:299–302. Although from 1975, this paper dispelled the erroneous contention that hallucinogens cause chromosomal damage.

    Article  PubMed  CAS  Google Scholar 

  50. Horgan J: Peyote on the brain: is the secret to alcoholism and other addictions locked up in hallucinogenic drugs? Discover Magazine 2003, 24:68–74.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biological Psychiatry Laboratory, Alcohol and Drug Abuse Research Center, McLean Hospital, 115 Mill Street, 02478, Belmont, MA, USA

    John H. Halpern MD

Authors
  1. John H. Halpern MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halpern, J.H. Hallucinogens: An update. Curr Psychiatry Rep 5, 347–354 (2003). https://doi.org/10.1007/s11920-003-0067-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-003-0067-4

Keywords

Search

Navigation